Feasibility of lymphoscintigraphy and sentinel node biopsy in patients with renal cell carcinoma - Sentinel node procedure in kidney cancer

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•1. Localized parenchymal tumor of the kidney not exceeding 10 cm (cT1-cT2)
•2. No metastatic disease on imaging and clinical examination (cN0, cM0)
•3. Age: 18 to 65 years
•4. Life expectancy > 3 months
•5. WHO performance status 0 or 1 and fit for surgery
•6. Written informed consent obtained from the patient after having been informed about the objectives of the study and the medication used.
•7. Blood counts: Leucocytes > 3.0 x 109/l, platelets > 100 x 109/l, hemoglobin > 6.0 mmol/l.
•8. Serum bilirubin, ASAT, ALAT and creatinin within 1.5 times of upper limit of reference values of laboratory.
•9. No prior systemic treatment with biological response modifiers, tyrosine-kinase inhibitors, monoclonal antibodies or chemotherapy.

•1. Parenchymal kidney tumor larger than 10 cm
•2. clinically metastatic disease or at imaging
•3. Patients in whom surgery is no option due to comorbidity
•4. Current cardiovascular disease, hematopoetic, pulmonary, hepatic or renal dysfunction or WHO performance status > 1.
•5. Previous immunotherapy, therapy with tyrosine-kinase inhibitors, monoclonal antibodies or chemotherapy.
•6. Corticosteroid and/ or other immunosuppressive therapies.
•7. Prior malignancies. In case of NED the period should be > 5 years.
•8. Pregnancy

发起方

Antoni van Leeuwenhoek Ziekenhuis